⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
HROW News
Harrow, Inc. Common Stock
Form 8-K
sec.gov
HROW
Harrow Acquires Global Rights to TYRVAYA®, the First and Only FDA-Approved Nasal Spray for Dry Eye Disease
globenewswire.com
HROW
Harrow Acquires Global Rights to TYRVAYA®, the First and Only FDA-Approved Nasal Spray for Dry Eye Disease
globenewswire.com
HROW
Harrow To Report Second Quarter 2026 Financial Results After Market Close on August 10, 2026
globenewswire.com
HROW
Samsung Bioepis and Harrow Present Interim Data from a Large-Scale Post-Marketing Surveillance Study on SB11 (BYOOVIZ® / AMELIVU®), a Biosimilar to Lucentis (ranibizumab), at ASRS 2026
globenewswire.com
HROW
Harrow Highlights Growing Clinical Evidence Supporting IHEEZO® and BYOOVIZ® at ASRS 2026 Annual Meeting
globenewswire.com
HROW
Harrow Announces Commercial Launch of BYOOVIZ® in the United States
globenewswire.com
HROW
Form 8-K
sec.gov
HROW
Harrow Re-Launches VERKAZIA® (cyclosporine ophthalmic emulsion) 0.1% for Vernal Keratoconjunctivitis, Addressing Significant Unmet Need in Pediatric Eyecare
globenewswire.com
HROW
Form 8-K
sec.gov
HROW